SOURCE-LINKED STUDY SUMMARY
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Abstract summarizedQuality not appraised
- What was studied
- Two randomized, double-blind trials compared long-acting CJC-1295 with placebo, measuring growth hormone, IGF-I and drug-processing characteristics.
- Who / model studied
- Healthy adults aged 21–61 were studied for 28 and 49 days. The abstract does not report participant numbers.
- Studied dose & schedule
- Across two placebo-controlled healthy-adult trials lasting 28 and 49 days, CJC-1295 was injected subcutaneously as a single dose or on weekly or biweekly multiple-dose schedules. The abstract highlights 30 or 60 microg/kg, but does not link either amount to a specific schedule or list every ascending dose.
- What the study found
- After a single injection, average growth hormone rose 2- to 10-fold for at least six days and IGF-I rose 1.5- to 3-fold for 9–11 days. After repeated administration, IGF-I remained above baseline for up to 28 days. No serious adverse reactions were reported.
- Limitations & context
- No author-stated limitations were available in the abstract. The reported endpoints were hormone levels and pharmacokinetics, not demonstrated muscle gain or recovery benefits.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1210/jc.2005-1536